Recombinant Interleukin-11

The rIL-11 signal remained significant after adjustment for indication. Several case features strengthened concern for a possible causal association between recombinant interleukin-11 and atrial fibrillation reporting. IL-11 can promote profibrotic effects by stimulating cardiac fibroblasts through ERK pathway activity at physiological levels. Recombinant interleukin-11 was the strongest adjusted atrial fibrillation reporting signal in the study. Clinical trial evidence cited in the article found a higher incidence of atrial fibrillation or atrial flutter with recombinant interleukin-11 than placebo. Recombinant interleukin-11 is used to prevent or treat chemotherapy-induced thrombocytopenia.